Molecular mechanisms and future uses of antiestrogens

Molecular Aspects of Medicine

Volumn 18, Issue 3, 1997, Pages 167-247

  Jordan, V Craig ^a   Gradishar, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; DRUG CARCINOGENICITY; DRUG MECHANISM; DRUG USE; ENDOMETRIUM CANCER; ISCHEMIC HEART DISEASE; LIVER CELL CARCINOMA; OSTEOPOROSIS;

EID: 0030757140     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0098-2997(96)00015-5     Document Type: Review

References (295)

1. Abe, O., Enomote, K., Fujiwara, K., Izuo, M., Iino, Y., Tominaga, T., Hayashik Takatani, O., Kugai, N. and Yoshida, M. (1990). Phase I study of FK 435. Japanese Journal of Cancer Clinics 36, 903-913.
2. Abe, O., Enomote, K., Fujiwara, K., Izumo, M., Iino, Y., Tominaga, T., Hayashik Takatani, O., Kugai, N. and Yoshida, M. (1991). Japanese early phase II study of droloxifene in the treatment of advanced breast cancer. American Journal of Clinical Oncology 14, 540-541.
3. Ahlemann, L. M., Staab, H. J., Loser, R., Seibel, K. and Huber, H. J. (1988). Inhibition of growth of human cancer by intermittent exposure to the antiestrogen droloxifene. Tumor Diagnosis and Therapy 9, 41-46.
4. Allan, G. F., Leng, X., Tsai, S. T., Weigel, N. L., Edwards, D. P., Tsai, M. J. and O'Malley, B. W. (1992). Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. Journal of Biology and Chemistry 267, 19513-19520.
5. Allen, K. E., Clark, E. R. and Jordan, V. C. (1980). Evidence for the metabolic activation of nonsteroidal antioestrogens: a study of structure activity relationships. British Journal of Pharmacology 71, 87-91.
6. Antilla, M., Valvaara, R., Kivinen, S. and Maenpaa, J. (1990). Pharmacokinetics of toremifene. Journal of Steroid Biochemistry. 36, 249-252.
7. Asaishi, K., Tominaga, T., Abe, O., Izuo, M. and Nomula, Y. (1993). Efficacy and safety of high dose NK 622 (toremifene citrate) in tamoxifen failed patients with breast cancer [in Japanese]. Gan to Kagaku Ryoho 20, 91-99.
8. Assikis, V. J. and Jordan, V. C. (1995). Gynecological effects of tamoxifen and the association with endometrial cancer. International Journal of Gynecology and Obstetrics 49, 241-257.
9. Assikis, V. J., Neven, P., Jordan, V. C. and Vergote I. (1996). A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. European Journal of Cancer 32A, 1464-1476.
10. Avigan, J., Steinberg, D., Vroman, H. E., Thompson, M. J. and Mosettig, E. (1960). Studies of cholesterol biosynthesis: the identification of desmosterol in serum and tissues of animals and man treated with MER-29. Journal of Biology and Chemistry 235, 3123-3126.
11. Barakat, R. R. (1997). Benign and hyperplastic changes associated with tamoxifen use. Oncology 11 (Suppl), 35-37.
12. Barakat, R. R., Wong, G., Curtin, J. D., Vlamis, V. and Hoskins, W. J. (1994). Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histological features. Gynecology and Oncology 55, 164-168.
13. Beatson, G. T. (1896). On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2, 104-107.
14. Bedford, G. R. and Richardson, D. N. (1966). Preparation and identification of cis and tram isomers of a substituted triarylethylene. Nature 212, 733-734.
15. Bellmunt, J. and Sole, L. (1991). European early phase II dose finding study of droloxifene in advanced breast cancer. American Journal of Clinical Oncology 14, 536-539.
16. Bertelli, G., Pronzato, P., Amoroso, D., Cusmano, M. P., Conte, P. F., Montagna, G., Bertolini, S. and Rosso, R. (1988). Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III. Breast Cancer Research and Treatment 12, 307-310.
17. Berthois, Y., Katzenellenbogen, J. A. and Katzenellenbogen, B. S. (1986). Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen responsive cells in culture. Proceedings of the National Academy of Science USA 83, 2496-2500.
18. Berthou, F. and Dreano, Y. (1993). High performance liquid chromatographic analysis of tamoxifen, toremifene and their major human metabolites. J. Chromatogr. B. Biomed. Appl. 616, 117-127.
19. Bilimoria, M. M., Assikis, V. J. and Jordan, V. C. (1996). Should adjuvant tamoxifen treatment be stopped at 5 years? Cancer Journal from Scientific American 2, 140-150.
20. Bishop, J., Muray, R., Webster, L., Pitt, P., Stokes, K., Fennessy, A., Olveri, I. and Leber, G. (1992). Phase I clinical and pharmacokinetics study of high dose toremifene in postmenopausal patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology 30, 174-178.
21. Black, L. J., Jones, C. D. and Falcone, J. F. (1983). Antagonism of estrogen action with a new benzothiophene-derived antiestrogen. Life Sciences 32, 1031-1036.
22. Black, L. J., Sato, M., Rowley, E. R., Magee, D. E., Bekele, A., Williams, D. C., Cullinan, G. J., Bendele, R., Kauffman, R. F. and Bensch, W. R. (1994). Raloxifene (LY139481 HC1) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. Journal of Clinical Investigations 93, 63-69.
23. Bloom, H. J. G., Roe, F. J. C. and Mitcheley, B. C. V. (1967). Sex hormones and renal neoplasia: inhibition of tumor of hamster kidney by an estrogen antagonist, an agent of possible therapeutic value in man. Cancer 20, 2118-2120.
24. Boccardo, F., Bruzzi, P., Rubagotti, A., Nicolo, G. U. and Rosso, R. (1981). Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 38, 281-2825.
25. Bowler, J., Lilley, T. J., Pittman, J. D. and Wakeling, A. E. (1989). Novel steroidal pure antiestrogens. Steroids 54, 71-99.
26. Boyd, S. (1990). On oophorectomy in cancer of the breast. British Medical Journal 2, 1161-1167.
27. Breast Cancer Trials Committee, Scottish Trials Office (1987). Adjuvant tamoxifen in the management of operable breast cancer. The Scottish Trials. Lancet ii, 171-175.
28. Bucourt, R., Vignau, M., Torelli, V., Richard-Roytt, A., Geynet, C., Secco-Millet, C., Redcailh, G. and Baulieu, E. E. (1978). New biospecific adsorbents for the purification of estradiol receptor. Journal of Biology and Chemistry 253, 8221-8228.
29. Buzdar, A. U., Kau, S., Hortobagyi, G. N., Theriault, R. L., Booser, D., Holmes, F. A., Walters, R. and Krakoff, I. H. (1994). Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology 33, 313-316.
30. Buzdar, A. U., Marcus, C., Holmes, F., Hug, V. and Hortobagyi, G. N. (1988). Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 45, 344-345.
31. Canney, P. A., Griffiths, T., Latief, T. N. and Priestman, T. J. (1987). (Letter). Clinical significance of tamoxifen withdrawal response. Lancet i, 36.
32. Carmichael, P. L., Ugwumadu, A. H. N., Neven, P., Herwe, A. J., Poon, G. K. and Phillips, D. H. (1996). Lack of genotoxicity of tamoxifen in human endometriurn. Cancer Research 56, 1475-1479.
33. Carnochan, P., Trivedi, M., Young, H., Eccles, S., Potter, G., Haynes, B. and Ott, R. (1994). Biodistribution and kinetics of pyrrolidino-4-iodo-tamoxifen: prospects for pharmacokinetic studies using PET. Journal of Nuclear Biology and Medicine 38, 96-98.
34. Chander, S. K., McCague, R., Lugmani, Y., Newton, C., Dowsett, M., Jarman, M. and Coombes, R. C. (1991). Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Research 51, 5851-5858.
35. Clemens, J. A., Bennett, D. R., Black, L. J. and Jones, C. D. (1983). Effects of a new antiestrogen keoxifene (LY156758) on growth of carcinogen induced mammary tumors and on LH and prolactin levels. Life Sciences 32, 2869-2875.
36. Cole, M. P., Jones, C. T. A. and Todd, I. D. H. (1971). A new antioestrogenic agent in late breast cancer: an early clinical appraisal of ICI 46,474. British Journal of Cancer 25, 270-275.
37. Cole, M. P., Jones, C. T. A. and Todd, I. D. H. (1972). The treatment of advanced carcinoma of the breast with the antineoplastic agent tamoxifen (ICI 46,474) - a series of 96 patients. Advances in Antimicrobial Antineoplasia and Chemotherapy 2, 529-531.
38. Colletta, A. A., Wakefield, L. M., Howell, F. V., Van Roozendaal, K. E., Danielpour, D., Ebbs, S. R., Sporn, M. B. and Baum, M. (1990). Antiestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. British Journal of Cancer 62, 405-409.
39. Cook, L. S., Weiss, N. S., Schwartz, S. M., White, E., McKnight, B., Moore, D. E. and Daling, J. R. (1995). Population based study of tamoxifen therapy and subsequent ovarian, endometrial and breast cancers. Journal of the National Cancer Institute 87, 1359-1364.
40. Coombes, R. C., Haynes, B. P., Dowsett, M., Quigley, M., English, J., Judson, I. R., Griggs, L. J., Potter, G. A., McCague, R. and Jarman, M. (1995). Idoxifene: report of a phase I study in patients with metastatic breast cancer. Cancer Research 55, 1070-1074.
41. Dauvois, S., Danielian, P. S., White, R. and Parker, M. G. (1992). Antiestrogen ICI 164,384 reduces cellular estrogen receptor by increasing its turnover. Proceedings of the National Academy of Sciences USA 89, 4037-4041.
42. Dauvois, S., White, R. and Parker, M. G. (1993). The antiestrogen ICI 182 780 disrupts estrogen receptor nucleocytoplasmic shuttling. Journal of Cell Science 106, 1377-1388.
43. DeFriend, D. J., Howell, A., Nicholson, R. I., Anderson, E. T., Dowsett, M. L., Mansel, R. E., Blamey, R. W., Blandred, N. J., Robertson, J. F. and Saunders, C. (1994). Investigation of a pure new antiestrogen (ICI 182,780) in women with primary breast cancer. Cancer Research 54, 408-414.
44. DiSalle, E., Zaccheo, T. and Ornati, G. (1990). Antioestrogenic and antitumour properties of the new triphenylethylene derivative toremifene in the rat. Journal of Steroid Biochemistry 36, 203-206.
45. Dragan, Y. P., Langan-Fahey, S. M., Street, K., Vaughan, J., Jordan, V. C. and Pitot, H. C. (1994). Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fisher F344 rats. Breast Cancer Research and Treatment 31, 11-25.
46. Dragan, Y. P., Nawaysir, E., Fahey, S., Vaughn, J., McCague, Jordan, V. C. and Pitot, H. C. (1996). Effects of tamoxifen and two fixed ring analogs on multistage rat hepatocarcinogenesis. Carcinogenesis 17, 585-594.
47. Dragan, Y. P., Vaughan, J., Jordan, V. C. and Pitot, H. C. (1995). Comparison of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. Carcinogenesis 16, 2733-2741.
48. Draper, M. W., Flowers, D. E. and Hester, W. J. (1993). Effects of raloxifene (LY 139481 HCL) on biochemical markers of bone and lipid metabolism in healthy postmenopausal women. Proceeding of the Fourth International Symposium on Osteoporosis. Handelstrykkeriet Aalborg ApS., Aalborg, Denmark.
49. Draper, M. W., Flowers, D. E., Neild, J. A., Huster, W. J. and Zerbe, R. L. (1995). Antiestrogenic properties of raloxifene. Pharmacology 50, 209-217.
50. Dukes, M., Chester, R., Yarwood, L. and Wakeling, A. E. (1994). Effects of a non-steroidal pure antiestrogen ZM 189,154, on estrogen target organs of the rat including bones. Joumal of Endocrinology 141, 335-341.
51. Dukes, M., Miller, D., Wakeling, A. E. and Waterton, J. C. (1992). Antiuterotrophic effect of a pure antioestrogen ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. Journal of Endocrinology 135, 239-247.
52. Dukes, M., Waterton, J. C. and Wakeling, A. E. (1993). Antiuterotrophic effect of the pure antiestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. Journal of Endocrinology 138, 203-210.
53. Duncan, G. W., Lyster, S. C. and Clark, J. J. (1963). Antifertililty activity of two diphenyl-dihydronaphthalene derivatives. Proceeding of the Society of Experimental Biology and Medicine 112, 439-442.
54. Early Breast Cancer Trialists' Collaborative Group (1988). Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. New England Journal of Medicine 319, 1681-1692.
55. Early Breast Cancer Trialists' Collaborative Group (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339, 1-15.
56. Ebbs, S. R., Roberts, J. and Baum, M. (1990). Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication. Journal of Steroid Biochemistry 36, 239.
57. Eppenberger, U., Wosikowski, K. and Kung, W. (1991). Pharmacologic and biologic properties of Droloxifene, a new antiestrogen. American Journal of Clinical Oncology 14, s5-s14.
58. Ernst, S., Hite, G., Cantrell, J. S., Richardson, A. Jr. and Benson, H. D. (1976). Stereochemistry of geometric isomers of clomiphene: A correction of the literature and re-examination of structure activity relationships. Journal of Pharmacological Science 65, 148-150.
59. Evans, G. L., Bryant, H. U., Magee, D., Sato, M. and Turner, R. T. (1994). The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134, 2283-2288.
60. Falkson, H. C., Gray, R., Wolberg, W. A., Gilchrist, K. W., Harris, J. E., Tormey, D. C. and Falkson, G. (1990). Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer. An Eastern Cooperative Oncology Group Phase III Study. Journal of Clinical Oncology 8, 599-607.
61. Fawell, S. E., White, R., Hoare, S., Sydenham, M., Page, M. and Parker, M. G. (1990). Inhibition of estrogen receptor DNA binding by the pure antiestrogen ICI 164 384 appears to be mediated by impaired receptor dimerization. Proceedings of the National Academy of Science 87, 6883-6887.
62. Fisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerman, D. L. and Clonin, W. M. (1994). Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. Journal of the National Cancer Institute 86, 527-537.
63. Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerman, D. L. and Fisher, E. R. (1989). A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor positive tumors. New England Journal of Medicine 320, 429-434.
64. Fisher, B., Redmond, C., Brown, A., Fisher, E. R., Wolmark, N., Bowman, D., Plotkin, D., Wolter, J., Bornstein, R. and Legault-Poisson, S. (1986). Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer. 5 year results from the National Surgical Adjuvant Breast and Bowel Project Trial. Journal of Clinical Oncology 4, 459-471.
65. Fisher, B., Redmond, C., Brown, A., Wickerman, D. L., Wolmark, N., Allegra, J., Escher, G., Lippman, M., Savlov, E. and Wittliff, J. (1983). Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. Journal of Clinical Oncology 1, 227-241.
66. Fornander, T., Rutqvist, L. E., Cedermark, B., Glas, U., Mattsson, A., Silfverswaard, C., Skoog, L., Somell, A., Theve, T. and Wilking, N. (1989). Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet i, 117-120.
67. Fornander, T., Rutqvist, L. E., Sjoberg, H. E., Blomqvist, L., Mattsson, A. and Glas, U. (1990). Long term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. Journal of Clinical Oncology 8, 1019-1024.
68. Frantz, I. D., Mobberley, M. L. and Schroepfer, G. T. (1966). Effects of MER-29 on the intermediate metabolism of cholesterol. Progress in Cardiovascular Disorders 2, 511-518.
69. Furr, B. J. A. and Jordan, V. C. (1984). The pharmacology and clinical uses of tamoxifen. Pharmacology and Therapeutics 25, 127-205.
70. Gallagher, A., Chambers, T. J. and Tobias, J. H. (1993). The estrogen antagonist ICI 182,780 reduces cancellous bone volumes in female rats. Endocrinology 133, 2787-2791.
71. 24 unsaturated sterols of rat skin. Archives of Biochemistry and Biophysics 101, 108-115.
72. Geisler, J., Ekse, D. and Hosch, S. (1995). Influence of droloxifene (3-hydroxytamoxifen) 40 mg daily on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology 55, 193-195.
73. Gibson, M. K., Nemmers, L. A., Beckman, W. C., Davis, V. L., Curtis, S. W. and Korach, K. S. (1991). The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129, 2000-2010.
74. Gorski, J., Toft, D., Shyamala, G., Smith, D. and Notides, A. (1968). Homone receptors: studies on the interaction of estrogen with the uterus. Recent Progress in Hormone Research 24, 45-80.
75. Gottardis, M. M. and Jordan, V. C. (1987). The antitumor action of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Research 47, 4020-4024.
76. Gottardis, M. M. and Jordan, V. C. (1988). Development of tamoxifen stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Research 48, 5183-5187.
77. Gottardis, M. M., Ricchio, M. D., Satyaswaroop, P. G. and Jordan, V. C. (1990). Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Research 50, 3189-3192.
78. Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G. and Jordan, V. C. (1988). Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Research 48, 812-815.
79. Gottardis, M. M., Wagner, R. J., Borden, E. C. and Jordan, V. C. (1989a). Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Research 49, 4765-4769.
80. Gottardis, M. M., Jiang, S. Y., Jeng, M. H. and Jordan, V. C. (1989b). Inhibition of tamoxifen stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Research 49, 4090-4093.
81. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. and Orton, T. (1993). Two year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Research 53, 3919-3924.
82. Green, S. and Chambon, P. (1991). The oestrogen receptor: from perception to mechanism. In: Nuclear Hormone Receptors (Parker, M. G., eds), pp. 15-38. Academic Press, New York.
83. Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J. M., Argos, P. and Chambon, P. (1986). Human oestrogen receptor cDNA: Sequence, expression and homology with v-erb A. Nature 320, 139-143.
84. Greenblatt, R. B., Barfield, W. E., Jungck, E. C. and Ray, A. W. (1961). Induction of ovulation with MRL-41. Journal of the American Medical Association 178, 101-104.
85. Greenblatt, R. B., Roy, S., Mahesh, V. B., Barfield, W. E. and Jungck, E. L. (1962). Induction of ovulation with clomiphene citrate. American Journal of Obstetrics and Gynecology 84, 900-912.
86. Greene, G. L., Gilna, P., Waterfield, M., Baker, A., Hort, Y. and Shine, J. (1986). Sequence and expression of human estrogen receptor complementary DNA. Science 231, 1150-1154.
87. Greenwald, G. S. (1965). Effects of a dihydronaphthalene derivative (U-11, 100A) on pregnancy in the rat. Fertility and Sterility 16, 185-194.
88. Grenman, R. L., Laine, K. M., Klemi, P. J., Grenman, S., Hayashida, D. J. and Joensuu, H. (1991). Effect of the antiestrogen toremifene on growth of the human mammary carcinoma cell line MCF-7. Journal of Cancer Research and Clinical Oncology 117, 223-226.
89. Grill, H. J. and Pollow, K. (1991). Pharmacokinetics of droloxifene and its metabolites in breast cancer patients. American Journal of Clinical Oncology 14(2), s21-s29.
90. Gunderson, S. (1990). Toremifene, a new antiestrogenic compound in the treatment of advanced breast cancer. Phase II study. European Journal of Cancer 24A, 785-790.
91. Gylling, H., Pyrhonen, S., Mantyla, E., Maenpaa, H., Kangas, L. and Miettinen, T. A. (1995). Tamoxifen and toremifene lower serum cholesterol by inhibition of Δ8-cholestenol conversion to lathosterol in women with breast cancer. Journal of Clinical Oncology 13, 2900-2905.
92. Haarstad, H., Gundersen, S., Wist, E., Raabe, N., Mella, O. and Kvinnsland, S. (1992). Droloxifene - a new anti-estrogen phase II study in advanced breast cancer. Acta Oncologica 31, 425-428.
93. Haddow, A., Watkinson, J. M. and Paterson, E. (1994). Influence of synthetic oestrogens upon advanced malignant disease. British Medical Journal 2, 393-398.
94. Halachmi, S., Marden, E., Martin, G., MacKay, H., Abbondanza, C. and Brown, M. (1993). Estrogen receptor associated proteins possible mediators of hormone-induced transcription. Science 264, 1455-1458.
95. Hamm, J. T., Tormey, D. C., Kohler, P. C., Haller, D., Green, M. and Shemano, I. (1991). Phase I study of toremifene in patients with advanced cancer. Journal of Clinical Oncology 9, 2036-2041.
96. Han, X. and Liehr, J. G. (1992). Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Research 52, 1360-1363.
97. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, K., Kaltenberg, O. P., Imondi, A. R. and Williams, G. M. (1993). Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl;CD (BR) rats. Cancer Research 53, 4534-4541.
98. Harper, M. J. K. and Walpole, A. L. (1966). Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 212, 87.
99. Harper, M. J. K. and Walpole, A. L. (1967). A new derivative of triphenylethylene: effect on implantation and mode of action in rats. Journal of Reproduction and Fertility 13, 101-119.
100. Hasman, M., Rattel, B. and Loser, R. (1994). Preclinical data for droloxifene. Cancer Letters 84, 101-116.
101. Hayes, D. F., Van Zyl, J. A., Hacking, A., Goedhals, L., Bezwoda, W. R., Maillard, J. A., Jones, S. E., Vogel, C. L., Berus, R. F. and Shemano, I. (1995). Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. Journal of Clinical Oncology 113, 2556-2566.
102. Hecker, E., Vegh, I., Levy, C. M., Magin, C. A., Martinez, J. C., Loureiro, J. and Garola, R. E. (1974). Clinical trial of clomiphene in advanced breast cancer. Europearn Journal of Cancer 10, 747-749.
103. Herbst, A. L., Griffiths, C. T. and Kistner, R. W. (1964). Clomiphene citrate in disseminated mammary carcinoma. Cancer Chemotherapy Reports 43, 39-41.
104. Hietanen, T., Baltina, D., Johansson, R., Numminen, S., Hakala, T., Helle, L. and Valavaara, R. (1990). High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer - an ongoing phase-II multicenter Finnish-Latvian cooperative study. Breast Cancer Research and Treatment 16, 37-40.
105. Hindy, I., Juhos, E., Szanto, J. and Szamel, I. (1990). Effect of toremifene in breast cancer patients. Preliminary communication. Journal of Steroid Biochemistry 36, 225-226.
106. Hirsimaki, P., Hirsimaki, Y., Nieminen, L. and Payne, B. J. (1993). Tamoxifen induces hepatocellular carcinoma in rat liver: A 1 year study with 2 antiestrogens. Archives of Toxicology 67, 49-59.
107. Hollander, W., Chobanian, A. V. and Wilkins, R. W. (1960). The effects of triparanol (MER-29) in subjects with and without coronary artery disease. Journal of the American Medical Association 174, 187-94.
108. Holtkamp, D. E. (1987). Research and development of clomiphene citrate. In: Recent Advances in Human Reproduction (Asch, R. H., ed.), pp. 17-27. Fondaizione per Gli Studi sulla riproduzione Umana.
109. Holtkamp, D. E., Greslin, S. C., Root, C. A. and Lerner, L. J. (1960). Gonadotropin inhibiting and antifecundity effects of chloramiphene. Proceedings of the Society of Experimental Biology and Medicine 105, 197-201.
110. Homesley, H. D., Shemano, I., Gams, R. A., Harry, D. S., Hickock, P. G., Rebar, R. W., Bun, R. C., Mullin, T. J., Wentz, A. C. and O'Toole, R. V. (1993). Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. American Journal of Clinical Oncology 16, 117-122.
111. Howell, A., DeFriend, D. J., Robertson, J. F. R., Blamey, R. W., Anderson, L., Anderson, E., Sutcliffe, F. A. and Walton, P. (1996). Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182,780 in women with breast cancer. British Journal of Cancer 74, 300-308.
112. Howell, A., DeFriend, D., Robertson, J., Blamey, R. and Walton, P. (1995). Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 345, 29-30.
113. Howell, A., Dodwell, D. J., Anderson, H. and Redford, J. (1992). Response after withdrawal of tamoxifen and progestogen in advanced breast cancer. Annals of Oncology 3, 611-617.
114. Huovinen, R. L., Alanen, K. A. and Collan, Y. (1995). Cell proliferation in dimethylbenz(A) anthracene-induced rat mammary carcinoma treated with antiestrogen toremifene. Acta Oncologica 34, 479-485.
115. Huovinen, R., Kellokumpu-Lehtinen, P.-L. I. and Collanm, Y. (1994). Evaluating the response to antiestrogen toremifene treatment in DMBA-induced rat mammary carcinoma. International Journal of Experimental Pathology 75, 257-263.
116. Huovinen, R., Warri, A. and Collan, Y. (1993). Mitotic activity, apoptosis and TRPM-2 messenger RNA expression in DMBA-induced rat mammary carcinoma treated with antiestrogen toremifene. International Journal of Cancer 55, 685-691.
117. Huppert, L. C. (1979). Induction of ovulation with clomiphene citrate. Fertility and Sterility 31, 1-8.
118. Iino, Y., Takai, Y., Ando, T., Chwada, S., Yokoe, T., Sugamata, N., Takei, H., Houghchi, J., Iijima, K. and Morishita, Y. (1994). A new triphenylethylene derivative TAT-59: hormone receptors, insulin-like growth factor 1 and growth supression of hormone dependent MCF-7 tumors in athymic mice. Cancer Chemotherapy and Pharmacology 34, 372-376.
119. Jaiyesimi, I. A., Buzdar, A. U., Decker, D. A. and Hortobagyi, G. N. (1995). Use of tamoxifen for breast cancer twenty eight years later. Journal of Clinical Oncology 13, 513-529.
120. Jensen, E. V. and Jacobson, H. I. (1962). Basic guides to the mechanism of estrogen action. Recent Progress in Hormone Research 18, 387-414.
121. Jiang, S. Y., Wolf, D. M., Yingling, J. M., Chang, C. and Jordan, V. C. (1992). An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Molecular and Cell Endocrinology 90, 77-86.
122. Jones, C. D., Jevnikar, M. G., Pike, A. J., Peters, M. K., Black, L. J., Thompson, A. R., Falcone, J. F. and Clemens, J. A. (1984). Antiestrogens 2, structure activity studies in a series of 3-aroyl-2-(4-hydroxyphenyl)benzo [b] thiene-3-yl] [4-[2-(1-piperidinyl) ethoxy] phenyl] methanone hydrochloride (LY156,758) a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. Journal of Medicine and Chemistry 27, 1057-1066.
123. Jones, C. D., Suarez, T., Massey, E. H., Black, L. J. and Tinsley, F. C. (1979). Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthenyl] [4-(2-(1-p-pyrrolidinyl ethoxy)-phenyl] methanone methane sulfonic acid. Journal of Medicine and Chemistry 22, 962-966.
124. Jönsson, P. E., Malmberg, M., Bergljung, L. and Ingvar, C. (1991). Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifen treatment. AntiCancer Research 11, 873-876.
125. Jordan, V. C. (1974). Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. Journal of Steroid Biochemistry 5, 354.
126. Jordan, V. C. (1976). Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. European Journal of Cancer 12, 419-424.
127. Jordan, V.C. (1978). Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Rev. Endocrine Rel. Cancer October suppl, 49-55.
128. Jordan, V. C. (1983). Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogen: problems and potential for future clinical applications. Breast Cancer Research and Treatment 3, 573-586.
129. Jordan, V. C. (1984). Biochemical pharmacology of antiestrogen action. Pharmacological Reviews 36, 245-276.
130. Jordan, V. C. (1988). The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Research and Treatment 11, 197-209.
131. Jordan, V. C. (1993). Current view of the use of tamoxifen for the treatment and prevention of breast cancer. Gaddum Memorial Lecture. British Journal of Pharmacology 110, 507-517.
132. Jordan, V. C. (ed). (1994). Long-term Tamoxifen Treatment for Breast Cancer. University of Wisconsin Press, Madison.
133. Jordan, V. C. (1995a). Alternate antiestrogens and strategies for the prevention of breast cancer. Journal of Cell Biochemistry 22, 557-561.
134. Jordan, V. C. (1995b). Tamoxifen and tumorigenicity: a predictable concern. Journal of the National Cancer Institute 87, 623-626.
135. Jordan, V. C. (1995c). What if tamoxifen had been found to produce rat liver tumors in 1973? Annals of Oncology 6, 29-33.
136. Jordan, V. C. and Assikis, V. J. (1995). Tamoxifen and endometrial cancer: clearing up a controversy. Clinical Cancer Research 1, 467-472.
137. Jordan, V. C. and Gosden, B. (1983a). Differential antiestrogen actions in the immature rat uterus: a comparision of hydroxylated antiestrogens with high affinity for the estrogen receptor. Journal of Steroid Biochemistry 19, 1249-1258.
138. Jordan, V. C. and Gosden, B. (1983b). Inhibition of the uterotrophic activity of estrogens and antiestrogens by the short acting antiestrogen LY 117 018. Endocrinology 113, 463-468.
139. Jordan, V. C. and Morrow, M. (1994). Should clinicians be concerned about the carcinogenic potential of tamoxifen? European Journal of Cancer 30A, 1714-1721.
140. Jordan, V. C., Collins, M. M., Rowsby, L. and Prestwich, G. (1977). A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. Journal of Endocrinology 75, 305-316.
141. Jordan, V. C., Dix, C. J. and Allen, K. E. (1979). The effectiveness of long-term treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Adjuvant Therapy of Cancer. II (Salmon, S. E. and Jones, S. E., eds), pp. 19-26. Grune and Stratton, New York.
142. Jordan, V. C., Dix, C. J., Naylor, K. E., Prestwich, G. and Rowsby, L. (1978). Non-steroidal antiestrogens: their biological effects and potential mechanisms of action. Journal of Toxicology and Environmental Health 4, 364-390.
143. Jordan, V. C., Feniuk, L., Allen, K. E., Cotton, R. C., Richardson, D., Walpole, A. L. and Bowler, J. (1981). Structural derivatives of tamoxifen and estradiol 3-methyl ether as potential alkylating antioestrogens. European Journal of Cancer 17, 193-200.
144. Jordan, V. C., Lababidi, M. K. and Langan-Fahey, S. (1991). Suppression of mouse mammary tumorigenesis by long term tamoxifen therapy. Journal of the National Cancer Institute 83, 492-496.
145. Jordan, V. C., Lieberman, M. E., Cormier, E., Koch, R., Bagley, J. R. and Ruenitz, P. C. (1984). Structural requirements for the pharmacological activity of non-steroidal antiestrogens in vitro. Molecular Pharmacology 2261, 272-278.
146. Jordan, V. C., Phelps, E. and Lindgren, J. U. (1987). Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Research and Treatment 10, 31-35.
147. Jordan, V. C., Wolf, M., Mirecki, D. M., Whitford, D. A. and Welshons, W. V. (1988). Hormone receptor assays: clinical usefullness in the management of carcinoma of the breast. Critical Reviews of Clinical Laboratory Science 26, 97-152.
148. Kangas, L. (1990a). Review of the pharmacological properties of toremifene. Journal of Steroid Biochemistry 36, 191-195.
149. Kangas, L. (1990b). Biochemical and pharmacological effects of toremifene metabolites. Cancer Chemotherapy and Pharmacology 27, 8-12.
150. Kangas, L., Nieminen, A.-L., Blanco, G., Gronroos, M., Kallio, S., Karjalainen, A., Perilla, M., Sodervall, M. and Tiovola, R. (1986). A new triphenylethylene compound Fc-1157a. II antitumor effects. Cancer Chemotherapy and Pharmacology 17, 109-113.
151. Katzenellenbogen, B. S., Kendra, K. L., Norman, M. J. and Berthois, Y. (1987). Proliferation, hormonal responsiveness and estrogen receptor content of MCF-7 human breast cancer cell in the short and long-term absence of estrogens. Cancer Research 47, 4355-4360.
152. Kawamura, I., Mizota, T., Kondo, N., Shimomura, L. and Kohsaka, M. (1991). Antitumor effects of droloxifene, a new antiestrogen drug against 7,12 dimethylbenz (a) anthracene-induced mammary tumor in rats. Japan Journal of Pharmacology 57, 215-224.
153. Kawamura, I., Mizota, T., Lacey, E., Tanaka, Y., Manda, T., Shimomura, K. and Kohsaka, M. (1993). Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Japan Journal of Pharmacology 63, 27-34.
154. Ke, H. Z., Simmons, H. A., Pirie, C. M., Crawford, D. T. and Thompson, D. D. (1995). Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136, 2435-2441.
155. Kirby, T. J., Achorm, R. W. P., Perry, H. O. and Winkelmann, R. K. (1962). Cataract formation after triparanol therapy. Archives Ophthalmology 68, 486-491.
156. Kistner, R. B. (1965). Induction of ovulation with clomiphene citrate (Clomid). Obstetrics and Gynecology Surveys 20, 873-900.
157. Kistner, R. W. and Smith, O. W. (1960). Observations on the use of non-steroidal estrogen antagonist-MER-25. Surgical Forum 10, 725-729.
158. Kivinen, S. and Maenpaa, J. (1990). Effect of toremifene on clinical hematological and hormonal parameters at different dose levels in healthy postmenopausal volunteers: phase I study. Journal of Steroid Biochemistry 36, 217-220.
159. Knabbe, C., Zugmaier, G., Schmahl, M., Dietel, M., Lippman, M. E. and Dickson, R. B. (1991). Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen and toremifene in MCF-7 cells. American Journal of Clinical Oncology 14, 15-20.
160. Koh, J. I., Kubota, T., Asanuma, F., Yamada, U., Kawamura, E., Hosoda, Y., Hashimoto, M., Yamamoto, O., Sakai, S. and Maeda, K. (1992). Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice. Journal of Surgical Oncology 51, 254-258.
161. Kohler, P. C., Hamm, J. F., Wiebe, V. J., DeGregario, M. W., Shemano, I. and Tormey, D. C. (1991). Phase I study of the tolerance and pharmacokinetics of tormifene in patients with cancer. Breast Cancer Research and Treatment 16, 19-26.
162. Konstantinova, M. M. and Gershanovich, M. L. (1990). Results of comparative clinical evaluation of antiestrogens toremifene and tamoxifen in locally advanced and disseminated breast cancer [in Russian] Vopr. Onkol. 36, 1182-1186.
163. Kraft, R. O. (1962). Triparanol in the treatment of disseminated mammary carcinoma. Cancer Chemotherapy Reports 25, 113-115.
164. Kristensen, B., Ejlertsen, B., Dalgaard, P., Larsen, L., Holmegaard, S. N., Transbol, I. and Mouridsen, H. T. (1994). Tamoxifen and bone metabolism in postmenopausal low risk breast cancer patients: a randomized study. Journal of Clinical Oncology 12, 992-997.
165. Laughlin, R. C. and Carey, T. F. (1962). Cataracts in patients treated with triparanol. Journal of the American Medical Association 181, 339-340.
166. Lee, R. W., Buzdar, A. U., Blumenschein, G. R. and Hortobagyi, G. N. (1986). Trioxifene mesylate in the treatment of advanced breast cancer. Cancer 57, 40-43.
167. Legha, S. S., Slavik, M. and Carter, S. K. (1976). Nafoxidine - an antiestrogen for the treatment of breast cancer. Cancer 38, 1535-1541.
168. Lien, E. A., Anker, G., Lonning, P. E. and Veland, D. M. (1995). Determination of droloxifene and two metabolites in serum by high pressure liquid chromatography. Therapy and Drug Monitoring 17, 259-265.
169. Lerner, L. J. (1981). The first non-steroidal antioestrogen-MER-25. In: Non-steroidal Antioestrogens: Molecular Pharmacology and Antitumour Activity (Sutherland, R. L. and Jordan, V. C., eds), pp. 1-16. Academic Press, Sydney.
170. Lerner, L. J. and Jordan, V. C. (1990). Development of antiestrogens and their use in breast cancer. Eighth Cain Memorial Lecture. Cancer Research 50, 4177-4189.
171. Lerner, L. J., Holthaus, J. F. and Thompson, C. R. (1958). A non-steroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl) -1-phenyl-2-p-methoxyphenyl-ethanol. Endocrinology 63, 295-318.
172. Lieberman, M. E., Gorski, J. and Jordan, V. C. (1983). An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. Journal of Biology and Chemistry 258, 4741-4745.
173. Lim, C. K., Zhi-Xin, Y., Lamb, J. H., White, I. N. H., De Matteis, F. and Smith, L. L. (1994). A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis 15, 589-593.
174. Loser, R., Seibel, K. and Eppenberger, U. (1985a). No loss of estrogenic and antiestrogenic activity after demethylation of droloxifene (3-OH tamoxifen). International Journal of Cancer 36, 701-703.
175. Loser, R., Seibel, K., Roos, W. and Eppenberger, U. (1985b). In vivo and in vitro antiestrogenic action of 3-hydroxy-tamoxifen, tamoxifen and 4-hydroxy-tamoxifen, European Journal of Cancer. Clinical Oncology 21, 900-985.
176. Love, R. R., Barden, H. S., Mazess, R., Epstein, S. and Chappell, R. J. (1994). Effect of tamoxifen on lumber spine bone mineral density in postmenopausal women after 5 years. Archives of Internal Medicine 154, 2585-2586.
177. Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P. and De Mets, D. L. (1992). Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New England Journal of Medicine 326, 852-856.
178. Love, R. R., Wiebe, D. A., Feyzi, J. M., Newcomb, P. A. and Chappell, R. J. (1995). Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. Journal of the National Cancer Institute 86, 1534-1539.
179. Love, R. R., Weibe, D. A., Newcomb, P. A., Cameron, L., Leventhal, H., Jordan, V. C., Feyzi, J. and DeMets, D. L. (1991). Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Annals of Internal Medicine 115, 860-864.
180. Maenpaa, J., Sonderatrom, K. O., Gronroos, M., Taina, E., Ganba, A. and Kangas, L. (1990). Effect of toremifene on estrogen primed vaginal mucosa in postmenopausal women. Journal of Steroid Biochemistry 36, 1221-223.
181. Magriples, U., Naftolin, F., Schwartz, P. E. and Carcangui, M. L. (1993). High grade endometrial carcinoma in tamoxifen treated breast cancer patients. Journal of Clinical Oncology 11, 485-490.
182. Manni, A., Arafah, B. and Pearson, O. H. (1981). Changes in endocrine status following antiestrogen administration to premenopausal and postmenopausal women. In: Non-steroidal Antioestrogens, Molecular Pharmacology and Antitumour Activity (Sutherland, R. L. and Jordan, V. C., eds), pp. 435-452. Academic Press, Sydney.
183. 32P-Post labelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16, 1651-1654.
184. Martin, P. M., Berthois, Y. and Jensen, E. V. (1988). Binding of antiestrogen exposes an occult antigenic determinant in the human estrogen receptor. Proceedings of the National Academy of Science 85, 2533-2537.
185. McCague, R., LeClercq, G., Legros, N., Goodman, J., Blackburn, G. M., Jarman, M. and Foster, A. P. (1989). Derivatives of tamoxifen. Dependency of estrogenicity on the 4 substituent. Journal of Medicine and Chemistry 32, 2527-2533.
186. McCague, R., Parr, I. B. and Haynes, B. P. (1990). Metabolism of the 4 iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites. Biochemical Pharmacology 40, 2277-2283.
187. McDonald, C. C. and Stewart, H. J. (1991). Fatal myocardial infarction in the Scottish tamoxifen trail. British Medical Journal 303, 435-437.
188. McDonald, C. C., Alexander, F. E., Whyte, B. W., Forrest, A. P., McDonald, C. C. and Stewart, H. J. (1995). Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. British Medical Journal 311, 977-980.
189. McDonnell, D. P., Clemm, D. L., Hermann, T., Goldman, M. E. and Pike, J. W. (1995). Analysis of estrogen receptor function reveals three distinct classes of antiestrogens. Molecular Endocrinology 9, 659-669.
190. McGuire, W. L., Carbone, P. P. and Vollmer, E. P. (eds) (1975). Estrogen Receptors in Human Breast Cancer. Raven Press, New York.
191. W. S. Merrill Company (1967). Clomiphene Citrate (Clomid). Clinical Pharmacology and Therapeutics 8, 891-897.
192. Metzger, D., White, J. and Chambon, P. (1988). The human estrogen receptor functions in yeast. Nature 334, 31-36.
193. Metzler, M. and Schiffmann, D. (1991). Structural requirements for the in vitro transformation of Syrian hamster embryo cells by stilbene estrogens and triphenylethylene-type antiestrogens. American Journal of Clinical Oncology 14(2), s30-s35.
194. Modig, H., Borgstrom, M., Nilsson, I. and Westman, G. (1990). Phase II clinical study of toremifene in patients with metastatic breast cancer. Journal of Steroid Biochemistry 36, 235-236.
195. Moorthy, B., Sriram, P., Pathak, D., Bodell, W. J. and Randerath, K. (1996). Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Research 56, 53-57.
196. Morrow, M. and Jordan, V. C. (1993). Molecular mechanism of resistance to tamoxifen therapy in breast cancer. Archives of Surgery 128, 1187-1191.
197. Muhleman, K., Cook, L. S. and Weiss, N. S. (1994). The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977. Breast Cancer Research and Treatment 30, 201-204.
198. Murphy, C. S., Pink, J. J. and Jordan, V. C. (1992). Characterization of a receptor-negative, hormone non responsive clone derived from T47D human breast cancer cell line kept under estrogen free conditions. Cancer Research 50, 7285-7292.
199. Nicholson, R. I., Walker, K. J., Bouzukar, N., Wills, R. J., Gee, J. M., Rushmere, N. K. and Davies, P. (1990). Estrogen deprivation in breast cancer. Clinical, experimental and biological aspects. Annals of the New York Academy of Science 595, 316-327.
200. Nolvadex Adjuvant Trial Organization [NATO] (1983). Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Interim analysis at 4 years. Lancet i, 257-261.
201. Nolvadex Adjuvant Trial Organization [NATO] (1988). Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Interim analysis at eight years. British Journal of Cancer 57, 608-611.
202. Nomura, Y., Tominaga, T., Abe, O., Izuo, M. and Ogawa, N. (1993). Clinical evaluation of NK 22 (toremifene citrate) in advanced or recurrent breast cancer - a comparative study by a double blind method with tamoxifen [in Japanse]. Gan to Kagaku Ryoho 20, 247-258.
203. Osborne, C. K. (in press). Tamoxifen in the treatment of breast cancer. New England Journal of Medicine.
204. Osborne, C. K., Coronado, E. B. and Robinson, J. P. (1987). Human breast cancer in athymic nude mice: cytostatic effects of long-term antiestrogenic activity. European Journal of Cancer 23, 1189-1196.
205. Osborne, C. K., Coronado-Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McClelland, R. A., Manning, D. L. and Nicholson, R. I. (1995). Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human cancer. Journal of the National Cancer Institute 87, 746-750.
206. Osborne, C. K., Hobbs, K. and Clark, G. M. (1985). Effects of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Research 45, 584-590.
207. Osborne, C. K., Jarman, M., McCague, R., Coronado, E. B., Hilsenbeck, S. G. and Wakeling, A. E. (1994). The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemotherapy and Pharmacology 34, 89-95.
208. Osborne, M. R., Hewer, A., Hardcastle, I. R., Carmichael, P. L. and Phillips, D. H. (1996). Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Research 56, 66-71.
209. Palopoli, F. P., Feil, V. J., Allen, R. F., Holtkamp, D. E. and Richardson, A. Jr. (1967). Substituted aminoalkoxytriarylhaloethylenes. Journal of Medicine and Chemistry 10, 84-86.
210. Perry, J. J., Berry, D. A., Weiss, R. B., Hayes, D. M., Duggan, D. B. and Henderson, I. C. (1995). High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer. A phase II trial of the Cancer and Leukemia Group B (CALGB). Breast Cancer Research and Treatment 36, 35-40.
211. Pham, T. A., Elliston, J. F., Nawaz, Z., McDonnell, D. P., Tsai, M. J. and O'Malley, B. W. (1991). Antiestrogens can establish nonproductive receptor complexes and alter chomatin structure at target enhancers. Proceedings of the National Academy of Science USA 88, 3125-3129.
212. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. J., Hardcastle, I. R., Poon, G. K. and Deogh, A. (1996a). Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparison between human, rat and mouse hepatocytes. Carcinogenesis 17, 89-94.
213. Phillips, D. H., Hewer, A., White, I. N. H. and Farmer, P. B. (1994a). Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats. Carcinogenesis 15, 793-795.
214. Phillips, D. H., Hewer, A., Grover, P. L., Poon, G. K. and Carmichael, P. L. (1996b). Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients. Carcinogenesis 17, 1149-1152.
215. 5-ethyl]-tamoxifen inplicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis 15, 1487-1492.
216. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. J. and Poon, G. K. (1994c). α-hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Research. 54, 5518-5522.
217. Pink, J. J. and Jordan, V. C. (1996). Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Research 56, 2321-2330.
218. Pink, J. J., Bilimoria, M. M., Assikis, V. J. and Jordan, V. C. (1996b). Irreversible loss of the estrogen receptor in T47D breast cancer cells following prolonged estrogen deprivation. British Journal of Cancer (in press).
219. Pink, J. J., Fritsch, M., Bilimoria, M. M., Assikis, V. J. and Jordan, V. C. (in press). Cloning and Characterization of a 77 kilodalton oestrogen receptor isolated from a human breast cancer cell line. British Journal of Cancer.
220. Pink, J. J., Jiang, S. Y., Fritsch, M. and Jordan, V. C. (1995). An estrogen independent MCF-7 breast cancer cell line which contains a novel 80 kilodalton estrogen receptor related protein. Cancer Research 55, 2583-2590.
221. Pink, J. J., Wu, S. Q., Wolf, D. M., Bilimoria, M. M. and Jordan, V. C. (1996a). A novel 80 kilodalton human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Research 24, 962-969.
222. Poulin, R., Merand, Y., Poirier, D., Levesque, C., DuFour, J. M. and Labrie, F. (1989). Antiestrogenic properties of keoxifene, trans 4-hydroxytamoxifen and ICI 164,384, a new steroidal antiestrogen in ZR-75-1 human breast cancer cells. Breast Cancer Research and Treatment 14, 655-667.
223. Pongracz, K., Pathak, D. N., Nakamura, T., Burgingame, A. L. and Bodell, W. J. (1995). Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Research 55, 3012-3015.
224. Potter, G. A., McCague, R. and Jarman, M. (1994). A mechanistic hypothesis for DNA adduct formation by tamoxifen following oxidative metabolism. Carcinogenesis 15, 439-442.
225. Prentice, R. L. (1991). Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers. Preventive Medicine 20, 38-46.
226. Pyrhönen, S., Valavaara, R., Vuorinen, J. and Hajba, A. (1994). High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Research and Treatment 29, 223-228.
227. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 15, 2087-2094.
228. Raushning, W. and Pritchard, K. I. (1994). Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Research and Treatment 31, 83-94.
229. Reddel, R. R. and Sutherland, R. L. (1984). Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumor flare. European Journal of Cancer 20, 1419-1425.
230. Robinson, S. P. and Jordan, V. C. (1989). Antiestrogen action of toremifene on hormone-dependent, independent and heterogeneous breast tumor growth in the athymic mouse. Cancer Research 49, 1758-1762.
231. Robinson, S. P., Goldstein, D., Witt, P. L., Borden, E. C. and Jordan, V. C. (1990). Inhibition of hormone dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon α2. Breast Cancer Research and Treatment 15, 95-101.
232. Robinson, S. P., Langan-Fahey, S. M., Johnson, D. A. and Jordan, V. C. (1991). Metabolites, pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Met. Disp. 19, 36-43.
233. Robinson, S. P., Mauel, D. A. and Jordan, V. C. (1988). Antitumor actions of toremifene in the 7, 12 dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. European Journal of Cancer 24, 1817-1821.
234. Robson, J. M., Schonberg, A. and Fahim, H. A. (1938). Duration of action of natural and synthetic estrogens. Nature 142, 292-293.
235. Roos, W. K., Oeze, L., Loser, R. and Eppenberger, U. (1983). Antiestrogen action of 3-hydroxy-tamoxifen in the human breast cancer cell line MCF-7f Journal of the National Cancer Institute 71, 55-59.
236. Rose, D. P., Fischer, A. H. and Jordan, V. C. (1981). Activity of the antiestrogen trioxifene against N-nitrosomethylurea-induced rat mammary carcinomas. European Journal of Cancer and Clinical Oncology 17, 893-898.
237. Rutqvist, L. E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T. and Wilking, N. (1995). Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Journal of the National Cancer Institute 87, 645-651.
238. Rutqvist, L. E. and Matte son, A. (1993). Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of tamoxifen. The Stockholm Breast Cancer Study Group. Journal of the National Cancer Institute 85, 1398-1406.
239. Sargent, L. M., Dragan, Y. P., Suttler, C., Bahnub, N., Martin, P., Cisneros, A., Mann, J., Thorgursson, S., Jordan, V. C. and Pitot, H. C. (1996). Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. Carcinogenesis 17, 1051-1056.
240. Sabbah, M., Grouilleux, F., Sola, B., Redeuil, G. R. and Baulieu, E. E. (1991). Structural differences between the hormone and antihormone estrogen receptor complexes bound to the hormone response elements. Proceedings of the National Academy of Science USA 88, 390-394.
241. Satyaswaroop, P. G., Zaino, R. J. and Mortel, R. (1984). Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Research 44, 4006-4010.
242. Scholl, M., Huff, K. K. and Lippman, M. E. (1983). Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology 113, 611-617.
243. Smith, O. W., Smith, G. V. and Kistner, R. W. (1963). Action of MER-25 and of clomiphene on the human ovary. Journal of the American Medical Association 184, 122-130.
244. Sato, M., Kim, J., Short, L. L., Szemenda, C. W. and Bryant, H. U. (1995). Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized rats. Journal of Pharmacology and Experimental Therapy 272, 1251-1259.
245. Steinberg, D., Avigan, J. and Feigelson, E. G. (1961). Effects of triparanol (MER-29) on cholesterol biosynthesis and on blood sterol levels in man. Journal of Clinical Investigations 40, 884-888.
246. Stenbygaard, L. E., Herrstedt, J., Thomsen, J. F., Svendsen, K. R., Engelholm, S. A. and Dombernowsky, P. (1993). Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial. Breast Cancer Research and Treatment 25, 57-63.
247. Stewart, H.J., Forrest, A.P., Everington, D., McDonald, C.C., Dewar, J.A., Hawkins, R.A., Prescott, R.J.and George, W.D. (1996). on behalf of the Scottish Cancer Trials Breast Group, Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. British Journal of Cancer 74, 297-299.
248. Styles, J. A., Davies, A., Lim, C. K., De Matteis, F., Stanley, L. A., White, I. N., Yuan, Z. X. and Smith, L. L. (1994). Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450's. Carcinogenesis 15, 5-9.
249. Szamel, I., Hindy, I., Vincze, B., Eckardt, S., Kangas, L. and Hajba, A. (1994). Influence of toremifene on the endocrine regulation in breast cancer patients. European Journal of Cancer 30A, 154-158.
250. Tang, M. X., Jacobs, P., Stern, Y., Marder, K., Schofield, P., Garland, B., Andrews, H. and Mayeux, R. (1996). Effect of oestrogen during menopause on risk and age at onset of Alzheimers disease. Lancet 348, 429-433.
251. Tate, A. C., Greene, G. L., DeSombre, E. R., Jensen, E. V. and Jordan, V. C. (1984). Differences between estrogen and antiestrogen-estrogen receptor complexes identified with an antibody raised against the estrogen receptor. Cancer Research 44, 1012-1018.
252. Thompson, E. W., Katz, D., Shima, T. B., Wakeling, A. E., Lippman, M. E. and Dickson, R. B. (1989). ICI 164,384, a pure antagonist of estrogen stimulated MCF-7 cell proliferation and invasiveness. Cancer Research 49, 6929-6934.
253. Toko, T., Maksuo, K. I., Shibata, J., Wierzba, K., Nukatsuka, M., Takeda, S., Yamada, Y., Asao, T., Hirose, T. and Sato, B. (1992). Interaction of DP-TAT-59 an active metabolite of new triphenylethylene derivative (TAT-59) with estrogen receptors. Journal of Steroid Biochemistry and Molecular Biology 43, 507-514.
254. Toko, T., Sigimoto, Y., Matsuo, K. I., Yamasaki, R., Takeda, S., Wierzba, K., Asao, Y. and Yamada, Y. (1990). TAT-59 a new triphenylethylene derivative with antitumor activity against hormone dependent tumors. European Journal of Cancer 26, 397-404.
255. Tomas, E., Kauppila, A., Blanco, G., Apaja-Sarkkinen, M. and Laatikainen, T. (1995). Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecology and Oncology 59, 261-266.
256. Tominga, T., Abe, O., Izuo, M. and Nomurga, U. T. (1990). A phase I study of toremifene. Breast Cancer Research and Treatment 16, 27-27.
257. Tonetti, D. A. and Jordan, V. C. (1995). Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anticancer Drugs 9, 498-507.
258. Tonetti, D. A. and Jordan, V. C. (1996). The development of targeted antiestrogens to prevent diseases in women. Molecular Medicine Today 2, 218-223.
259. Tormey, D. C., Gray, R., Abeloff, M. D., Roseman, D. L., Gilchrist, K. W., Barylak, E. J., Stott, D. and Falkson, G. (1992). Adjuvant therapy with a doxarubicin regimen and long term tamoxifen in premenopausal breast cancer patients: A Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology 10, 1848-1855.
260. Turken, S., Siris, E., Selding, E., Flaster, E., Hyman, G. and Lindsay, R. (1989). Effect of tamoxifen on spinal bone density in women with breast cancer. Journal of the National Cancer Institute 81, 1086-1088.
261. Turner, R. T., Wakley, G. K., Hannon, K. S. and Bell, N. H. (1987). Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. Journal of Bone Mineral Research 2, 449-456.
262. Turner, R. T., Wakley, G. K., Hannon, K. S. and Bell, N. H. (1988). Tamoxifen inhibits osteoclast mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 122, 1146-1150.
263. Tyler, E. T., Olson, H. J. and Gotlieb, M. H. (1960). The induction of ovulation with an antiestrogen. International Journal of Fertility 5, 429-431.
264. Tzukerman, M. T., Esty, A., Santiso-Mere, D., Danelian, D., Parker, M. G., Stein, R. B., Pike, J. W. and McDonnell, D. P. (1994). Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Molecular Endocrinology 8, 21-30.
265. Valavaara, R. (1990). Phase II experience with toremifene in the treatment of ER-positive breast cancer of postmenopausal women. Cancer Investigations 8, 275-276.
266. Valavaara, R. and Pyrhonen, S. (1989). Low-dose toremifene in the treatment of estrogen-receptor-positive advanced breast cancer in postmenopausal women. Current Therapy and Research 46, 966-973.
267. Valavaara, R., Pyrhonen, S., Heikkinen, M., Rissanen, P., Blanco, G., Tholix, E., Nordman, E., Taskinen, D., Holsti, L. and Hajba, A. (1988). Toremifene, a new antiestrogenic treatment of advanced breast cancer Phase II study. European Journal of Cancer 24, 785-790.
268. Van de Velde, P., Nique, F., Bouchoux, F., Bremaud, J., Hameau, M. C., Lucas, D., Moratille, C., Viet, S., Philibert, D. and Teutsch, G. (1994). RU 58,668 a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. Journal of Steroid Biochemistry and Molecular Biology 48, 187-196.
269. van Leeuwen, F. E., Benraadt, J., Coebergh, J. W. W., Kiemeney, L. A., Gimbrere, C. H., Otter, R., Shouten, L. J., Damriuis, R. A., Bontenbal, M. and Diedenhorst, F. W. (1994). Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343, 448-452.
270. Vogel, C. L., Schoenfelder, J., Shermano, L., Hayes, D. F. and Gams, R. A. (1995). Worsening bone scan in the evaluation of antitumor response during hormonal therapy for breast cancer. Journal of Clinical Oncology 13, 1123-1328.
271. Vogel, C. L., Shemano, I., Schoenfelder, J., Gams, R. A. and Green, M. R. (1993). Multicenter phase II efficacy trial of toremifene in tamoxifen refractory patients with advanced breast cancer. Journal of Clinical Oncology 11, 345-350.
272. von Angerer, E., Krebel, N., Kager, M. and Ganss, R. (1990). 1-(Aminoalkyl) 2-phenyl-indoles as novel pure estrogen antagonists. Journal of Medicine and Chemistry 33, 2636-2640.
273. von Sallman, L., Grimes, P. and Collins, E. (1963). Triparanol-induced cataracts in rats. Archives Ophthamology 70, 1128-1136.
274. Wakeling, A. E. (1994). A new approach to breast cancer therapy-total estrogen ablation with pure antiestrogens. In: Long-term Tamoxifen Treatment for Breast Cancer. (Jordan, V. C., ed.), pp. 219-234. University of Wisconsin Press, Madison.
275. Wakeling, A. E. and Bowler, J. (1987). Steroidal pure antiestrogens. Journal of Endocrinology 112, R7-R10.
276. Wakeling, A. E. and Bowler, J. (1988). Novel antiestrogens without partial agonist activity. Journal of Steroid Biochemistry 31, 645-653.
277. Wakeling, A. E. and Valcaccia, B. (1983). Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens. Journal of Endocrinology 99, 455-464.
278. Wakeling, A. E., Dukes, M. and Bowler, J. (1991). A potent specific pure antiestrogen with clinical potential. Cancer Research 51, 3867-3873.
279. Walpole, A. L. and Paterson, E. (1949). Synthetic oestrogens in mammary cancer. Lancet ii, 783-789.
280. Ward, H. W. C. (1973). Antioestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. British Medical Journal i, 13-14.
281. Ward, R. L., Morgan, G., Dalley, D. and Kelly, P. J. (1993). Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Mineralogy 22, 87-94.
282. Warri, A. M., Huovinon, R. L., Laine, A. M., Mairtikainen, P. M. and Harkonen, P. L. (1993). Apoptosis in toremifene growth inhibition of human breast cancer cells in vivo and in vitro. Journal of the National Cancer Institute 85, 1412-1418.
283. Webster, L. K., Crinis, N. A., Stokes, K. H. and Bishop, J. F. (1991). High performance liquid chromatographic method for the determination of toremifene and its major human metabolites. J. Chromatogr. B. Biomed. Appl. 565, 482-487.
284. Welshons, W. V. and Jordan, V. C. (1987). Adaption of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. European Journal of Cancer 23, 1935-1939.
285. White, I. N. H., deMatteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C., Venitt, S., Hewer, A. and Philips, D. H. (1992). Genotoxic potential of tamoxifen and analogues in female Fischer 344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13, 2197-2203.
286. Wiebe, V. J., Benz, C., Shemano, I., Cadman, T. B. and DeGregorio, M. W. (1990). Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology 25, 247-251.
287. Williams, G. M., Iatropoulos, M. J., Djordjevic, M. V. and Kaltenberg, O. P. (1993). The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14, 315-317.
288. Williamson, J. G. and Ellis, J. P. (1973). The induction of ovulation by tamoxifen. Journal of Obstetrics and Gynaecology in the British Commonwealth 80, 844-847.
289. Winterfeld, G., Hauff, P., Grolich, M., Arnold, W., Fichtner, I. and Staab, H. J. (1992). Investigations of droloxifene and other hormonal manipulations on N-nitrosomethylurea-induced rat mammary tumours. Journal of Cancer Research and Clinical Oncology 119, 91-96.
290. Wiseman, H., Cannon, M., Astein, H. R. V. and Halliwell, B. (1993a). Tamoxifen inhibits lipid peroxidation in cardiac microsomes. Comparison with liver microsomes and potential relevance to the cardiovascular benefits associated with cancer prevention and treatment by tamoxifen. Biochemical Pharmacology 45, 1851-1855.
291. Wiseman, H., Paganga, G., Rice-Evans, C. and Halliwell, B. (1993b). Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen? Biochemical Journal 292, 635-638.
292. Witte, R. S., Pruitt, B., Tormey, D. C., Moss, S., Rose, D. P., Falkson, G., Carbone, P. P., Ramirez, G., Falkson, H. and Pretorius, F. J. (1986). A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinological effects. Cancer 57, 34-39.
293. Wolf, D. M., Langan-Fahey, S. M., Parker, C. J., McCague, R. and Jordan, V. C. (1993). Investigation on the mechanism of tamoxifen-stimulated breast tumor growth using nonisomerizable analogs of tamoxifen and metabolites. Journal of the National Cancer Institute 85, 806-812.
294. Wosikowski, K., Kung, W., Hasmann, M., Loser, R. and Eppenberger, U. (1993). Inhibition of growth factor activated proliferation by antiestrogens and effects on early gene expression of MCF-7 cells. International Journal of Cancer 53, 290-297.
295. Yang, N. N., Venugopalan, M., Hardikar, S. and Glasebrook, A. (1996). Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273, 1222-1225.